ENA-001

Last updated
ENA-001
GAL-021.svg
Clinical data
Routes of
administration
IV
ATC code
  • None
Legal status
Legal status
Identifiers
  • 2-[(N-Methyl-N-methoxy)amino]-4,6-bis(propylamino)-1,3,5-triazine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C11H22N6O
Molar mass 254.338 g·mol−1
3D model (JSmol)
  • CCCNc1nc(nc(N(C)OC)n1)NCCC
  • InChI=1S/C11H22N6O/c1-5-7-12-9-14-10(13-8-6-2)16-11(15-9)17(3)18-4/h5-8H2,1-4H3,(H2,12,13,14,15,16)
  • Key:FJNLCHNQVJVCPY-UHFFFAOYSA-N

ENA-001 (formerly GAL-021) [1] is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BKCa potassium channel, [2] although secondary mechanisms may also be involved. [3] It was developed by Galleon Pharmaceuticals, and is being tested in clinical trials for potential uses in post-operative care, [4] as well as more generally to counteract the respiratory depression which can be a side effect of opioid analgesic drugs. [5] [6] [7]

See also

Related Research Articles

<span class="mw-page-title-main">Agonist</span> Chemical which binds to and activates a biochemical receptor

An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the agonist, while an inverse agonist causes an action opposite to that of the agonist.

<span class="mw-page-title-main">Opioid</span> Psychoactive chemical

Opioids are a class of drugs that derive from, or mimic, natural substances found in the opium poppy plant. Opioids work in the brain to produce a variety of effects, including pain relief. As a class of substances, they act on opioid receptors to produce morphine-like effects.

<i>Mitragyna speciosa</i> Plant species, recreational drug (kratom)

Mitragyna speciosa is a tropical evergreen tree in the coffee family native to Southeast Asia. It is indigenous to Thailand, Indonesia, Malaysia, Myanmar, and Papua New Guinea, where it has been used in herbal medicine since at least the 19th century. It has also historically been used for chewing, smoking, and tea. Kratom has opiate properties and some stimulant-like effects.

<span class="mw-page-title-main">Nalbuphine</span> Opioid analgesic

Nalbuphine, sold under the brand names Nubain among others, is an opioid analgesic which is used in the treatment of pain. It is given by injection into a vein, muscle, or fat.

<span class="mw-page-title-main">Tianeptine</span> Atypical antidepressant

Tianeptine, sold under the brand names Stablon, Tatinol, and Coaxil among others, is an atypical tricyclic antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome.

<span class="mw-page-title-main">Analeptic</span> Drug class

An analeptic, in medicine, is a central nervous system stimulant. The term "analeptic" typically refers to respiratory analeptics. Analeptics are central nervous system (CNS) stimulants that include a wide variety of medications used to treat depression, attention deficit hyperactivity disorder (ADHD), and respiratory depression. Analeptics can also be used as convulsants, with low doses causing patients to experience heightened awareness, restlessness, and rapid breathing. The primary medical use of these drugs is as an anesthetic recovery tool or to treat emergency respiratory depression. Other drugs of this category are prethcamide, pentylenetetrazole, and nikethamide. Nikethamide is now withdrawn due to risk of convulsions. Analeptics have recently been used to better understand the treatment of a barbiturate overdose. Through the use of agents, researchers were able to treat obtundation and respiratory depression.

<span class="mw-page-title-main">BIMU8</span> Chemical compound

BIMU-8 is a drug which acts as a 5-HT4 receptor selective agonist. BIMU-8 was one of the first compounds of this class. The main action of BIMU-8 is to increase the rate of respiration by activating an area of the brain stem known as the pre-Botzinger complex.

μ-opioid receptor Protein-coding gene in the species Homo sapiens, named for its ligand morphine

The μ-opioid receptors (MOR) are a class of opioid receptors with a high affinity for enkephalins and beta-endorphin, but a low affinity for dynorphins. They are also referred to as μ(mu)-opioid peptide (MOP) receptors. The prototypical μ-opioid receptor agonist is morphine, the primary psychoactive alkaloid in opium and for which the receptor was named, with mu being the first letter of Morpheus, the compound's namesake in the original Greek. It is an inhibitory G-protein coupled receptor that activates the Gi alpha subunit, inhibiting adenylate cyclase activity, lowering cAMP levels.

<span class="mw-page-title-main">Trefentanil</span> Chemical compound

Trefentanil (A-3665) is an opioid analgesic that is an analogue of fentanyl and was developed in 1992.

<span class="mw-page-title-main">CX-546</span> Chemical compound

CX-546 is an ampakine drug developed by Cortex Pharmaceuticals.

<span class="mw-page-title-main">RWJ-394674</span> Chemical compound

RWJ-394674 is a drug that is used in scientific research. It is a potent, orally active analgesic drug that produces little respiratory depression. RWJ-394674 itself is a potent and selective agonist for δ-opioid receptors, with a Ki of 0.24 nM at δ and 72 nM at μ. However once inside the body, RWJ-394674 is dealkylated to its monodesethyl metabolite RWJ-413216, which is a potent agonist at the μ-opioid receptor and has less affinity for δ. The effect of RWJ-394674 when administered in vivo thus produces potent agonist effects at both μ and δ receptors through the combined actions of the parent drug and its active metabolite, with the δ-agonist effects counteracting the respiratory depression from the μ-opioid effects, and the only prominent side-effect being sedation.

<span class="mw-page-title-main">Potassium channel blocker</span> Several medications that disrupt movement of K+ ions

Potassium channel blockers are agents which interfere with conduction through potassium channels.

<span class="mw-page-title-main">Amiphenazole</span> Chemical compound

Amiphenazole (Daptazile) is a respiratory stimulant traditionally used as an antidote for barbiturate or opiate overdose, usually in combination with bemegride, as well as poisoning from other sedative drugs and treatment of respiratory failure from other causes. It was considered particularly useful as it could counteract the sedation and respiratory depression produced by morphine but with less effect on analgesia. It is still rarely used in medicine in some countries, although it has largely been replaced by more effective respiratory stimulants such as doxapram and specific opioid antagonists such as naloxone.

<span class="mw-page-title-main">Opioid overdose</span> Medical condition

An opioid overdose is toxicity due to excessive consumption of opioids, such as morphine, codeine, heroin, fentanyl, tramadol, and methadone. This preventable pathology can be fatal if it leads to respiratory depression, a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils, and unconsciousness, however its onset can depend on the method of ingestion, the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids, individuals who survived also faced adverse complications, including permanent brain damage.

<span class="mw-page-title-main">3-Hydroxymorphinan</span> Chemical compound

3-Hydroxymorphinan (3-HM), or morphinan-3-ol, is a psychoactive drug of the morphinan family. It is the racemic counterpart to norlevorphanol.

<span class="mw-page-title-main">IBNtxA</span> Chemical compound

IBNtxA, or 3-iodobenzoyl naltrexamine, is an atypical opioid analgesic drug derived from naltrexone. In animal studies it produces potent analgesic effects that are blocked by levallorphan and so appear to be μ-opioid mediated, but it fails to produce constipation or respiratory depression, and is neither rewarding or aversive in conditioned place preference protocols. These unusual properties are thought to result from agonist action at a splice variant or heterodimer of the μ-opioid receptor, rather than at the classical full length form targeted by conventional opioid drugs.

<span class="mw-page-title-main">Samidorphan</span> Opioid antagonist

Samidorphan is an opioid antagonist that in the form of olanzapine/samidorphan is used in the treatment of schizophrenia and bipolar disorder. Samidorphan reduces the weight gain associated with olanzapine. Samidorphan is taken by mouth.

<span class="mw-page-title-main">Trenbolone enanthate</span> Chemical compound

Trenbolone enanthate, known by the nickname Trenabol, is a synthetic and injected anabolic–androgenic steroid (AAS) and a derivative of nandrolone which was never marketed. It is the C17β enanthate ester and a long-acting prodrug of trenbolone. Trenbolone enanthate was never approved for medical or veterinary use but is used in scientific research and has been sold on the internet black market as a designer steroid for bodybuilders and athletes.

<span class="mw-page-title-main">Nalodeine</span> Chemical compound

Nalodeine, also known more commonly as N-allylnorcodeine, is an opioid antagonist that was never marketed but is notable as the first opioid antagonist to be discovered. It was first reported in 1915 and was found to block the effects of morphine in animals. This was followed by the clinical introduction of nalorphine (N-allylnormorphine) in 1954, naloxone (N-allyloxymorphone) in 1960, and naltrexone (N-methylcyclopropyloxymorphone) in 1963. Nalmefene (6-desoxy-6-methylene-naltrexone), another structurally related opioid antagonist derivative, was also subsequently introduced, in 1996. In animals, nalodeine both reverses morphine- and heroin-induced respiratory depression and acts as a respiratory stimulant in its own right. Similarly to nalorphine, nalodeine has also been found to act as an agonist of the κ-opioid receptor.

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

References

  1. Miller TL, Raab LM, Shaffer TH, Schweikert A, Diana F, Fort P, et al. (September 2022). "A Novel Agnostic Respiratory Stimulant as a Treatment for Apnea of Prematurity: A Proof-of-Concept Study". Cureus. 14 (9): e28900. doi: 10.7759/cureus.28900 . PMC   9544529 . PMID   36237747. S2CID   252141895.
  2. McLeod JF, Leempoels JM, Peng SX, Dax SL, Myers LJ, Golder FJ (November 2014). "GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers". British Journal of Anaesthesia. 113 (5): 875–883. doi: 10.1093/bja/aeu182 . PMID   24989775.
  3. Baby SM, Hoshi T, Peng S, Dax SL, Golder FJ, MacIntyre DE, Mannion JC (2012). "Comparison of the respiratory effects of GAL-021 in BK α subunit knockout (Slo1−/−) and wild-type mice". The FASEB Journal. 26 (1 Supplement): 704.30. doi: 10.1096/fasebj.26.1_supplement.704.30 .
  4. Golder FJ, Hewitt MM, McLeod JF (November 2013). "Respiratory stimulant drugs in the post-operative setting". Respiratory Physiology & Neurobiology. 189 (2): 395–402. doi: 10.1016/j.resp.2013.06.010 . PMID   23791825. S2CID   2558991.
  5. Baby SM, Gruber RB, Puskovic V, Peng S, Dax SL, Golder FJ, MacIntyre DE, Mannion JC (2012). "GAL-021, a novel respiratory stimulant, attenuates opioid–induced respiratory depression without compromising analgesia". The FASEB Journal. 26 (1 Supplement): 704.28. doi: 10.1096/fasebj.26.1_supplement.704.28 .
  6. van der Schier R, Roozekrans M, van Velzen M, Dahan A, Niesters M (4 September 2014). "Opioid-induced respiratory depression: reversal by non-opioid drugs". F1000Prime Reports. 6: 79. doi: 10.12703/P6-79 . PMC   4173639 . PMID   25343036.
  7. Roozekrans M, van der Schrier R, Okkerse P, Hay J, McLeod JF, Dahan A (September 2014). "Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers". Anesthesiology. 121 (3): 459–468. doi: 10.1097/ALN.0000000000000367 . PMID   25222672. S2CID   35738816.